Literature DB >> 28684103

Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development.

Hasina Samji1, Amanda Yu2, Margot Kuo2, Maryam Alavi3, Ryan Woods4, Maria Alvarez2, Gregory J Dore3, Mark Tyndall5, Mel Krajden5, Naveed Z Janjua6.   

Abstract

BACKGROUND & AIMS: We measured the timing of hepatitis B virus (HBV) and hepatitis C virus (HCV) diagnoses relative to the detection of decompensated cirrhosis (DC) and hepatocellular carcinoma (HCC) as an indicator of late hepatitis diagnosis.
METHODS: HBV and HCV diagnoses were defined relative to the diagnosis of DC or HCC such that HBV/HCV diagnoses within two years prior, at the time of or after HCC or DC diagnosis were considered late. We performed multivariable logistic regression to assess factors associated with late HBV/HCV diagnoses among those with DC or HCC.
RESULTS: From 1990 to 2012, 778/32,664 HBV cases (2.4%) and 3,925/57,866 HCV cases (6.8%) developed DC while 628/32,644 HBV cases (1.9%) and 902/57,866 HCV cases (1.6%) developed HCC. Among HBV and HCV cases with DC, 49% and 40% respectively were late diagnoses, as were 46% and 31% of HBV and HCV cases with HCC, respectively. HBV late diagnosis declined from 100% in 1992 to 11% and 26% in 2011, while HCV late diagnosis declined from 100% in 1992 to 16% and 14% in 2011 for DC and HCC respectively. In multivariable modelling, late HBV diagnosis was associated with mental illness and a fewer number of physician visits in the five years prior to HBV diagnosis. Late HCV diagnosis was also associated with fewer physician visits, while those with illicit drug use were less likely to be diagnosed late.
CONCLUSIONS: The proportion of late diagnoses has declined over time. People with better engagement with the healthcare system and with risk activities were diagnosed earlier. Lay summary: Late diagnosis of HBV and HCV represents a missed opportunity to reduce the risk of serious liver disease. Our results identify successes in earlier diagnosis over time using risk-based testing as well as groups that are being missed for screening such as those who do not see a physician regularly and those with serious mental illness.
Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cohort study; Epidemiology; HBV; HCC; HCV; Late diagnosis; Screening

Mesh:

Year:  2017        PMID: 28684103     DOI: 10.1016/j.jhep.2017.06.025

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  10 in total

Review 1.  Contextualizing Canada's hepatitis C virus epidemic.

Authors:  Mel Krajden; Darrel Cook; Naveed Z Janjua
Journal:  Can Liver J       Date:  2018-12-25

2.  GRK2 Suppresses Hepatocellular Carcinoma Metastasis and Invasion Through Down-Regulation of Prostaglandin E Receptor 2.

Authors:  Nan Li; Jing-Jing Wu; Ting-Ting Chen; Xiu-Qin Li; Jia-Jia Du; Shan Shan; Wei Wei; Wu-Yi Sun
Journal:  Onco Targets Ther       Date:  2020-09-28       Impact factor: 4.147

Review 3.  The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases.

Authors:  Henry Lowe; Ngeh Toyang; Blair Steele; Joseph Bryant; Wilfred Ngwa
Journal:  Int J Mol Sci       Date:  2021-08-31       Impact factor: 6.208

4.  Impact of availability of direct-acting antivirals for hepatitis C on Canadian hospitalization rates, 2012-2016.

Authors:  D Schanzer; L Pogany; J Aho; K Tomas; M Gale-Rowe; J C Kwong; N Z Janjua; J Feld
Journal:  Can Commun Dis Rep       Date:  2018-07-05

5.  Differing profiles of people diagnosed with acute and chronic hepatitis B virus infection in British Columbia, Canada.

Authors:  Mawuena Binka; Zahid A Butt; Stanley Wong; Mei Chong; Jane A Buxton; Nuria Chapinal; Amanda Yu; Maria Alvarez; Maryam Darvishian; Jason Wong; Gina McGowan; Mikhail Torban; Mark Gilbert; Mark Tyndall; Mel Krajden; Naveed Z Janjua
Journal:  World J Gastroenterol       Date:  2018-03-21       Impact factor: 5.742

6.  Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales.

Authors:  Syed Hassan Bin Usman Shah; Maryam Alavi; Behzad Hajarizadeh; Gail V Matthews; Marianne Martinello; Mark Danta; Janaki Amin; Matthew G Law; Jacob George; Heather Valerio; Gregory J Dore
Journal:  JHEP Rep       Date:  2022-08-06

7.  Late hepatitis C virus diagnosis among patients with newly diagnosed hepatocellular carcinoma: a case-control study.

Authors:  Shen-Shong Chang; Hsiao-Yun Hu; Yu-Chin Chen; Yung-Feng Yen; Nicole Huang
Journal:  BMC Gastroenterol       Date:  2022-09-17       Impact factor: 2.847

Review 8.  Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma.

Authors:  Pu Chen; Qiong-Xuan Fang; Dong-Bo Chen; Hong-Song Chen
Journal:  World J Gastrointest Oncol       Date:  2021-07-15

9.  A model-based framework for chronic hepatitis C prevalence estimation.

Authors:  Abdullah Hamadeh; Zeny Feng; Murray Krahn; William W L Wong
Journal:  PLoS One       Date:  2019-11-21       Impact factor: 3.240

10.  Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation.

Authors:  Shu Su; William Cw Wong; Zhuoru Zou; Dan Dan Cheng; Jason J Ong; Polin Chan; Fanpu Ji; Man-Fung Yuen; Guihua Zhuang; Wai-Kay Seto; Lei Zhang
Journal:  Lancet Glob Health       Date:  2022-02       Impact factor: 26.763

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.